Excision repair cross-complementation group 1 expression predicts response and survival in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy

Histopathology. 2011 Sep;59(3):564-7. doi: 10.1111/j.1365-2559.2011.03943.x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / analysis*
  • Chemoradiotherapy
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • DNA-Binding Proteins / biosynthesis*
  • Endonucleases / biosynthesis*
  • Female
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Uterine Cervical Neoplasms / metabolism*
  • Uterine Cervical Neoplasms / mortality
  • Uterine Cervical Neoplasms / therapy

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • ERCC1 protein, human
  • Endonucleases
  • Cisplatin